Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 14;8(9):2244-2247.
doi: 10.1182/bloodadvances.2023012348.

Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac disease

Lauren E Merz  1   2 , Duaa AbdelHameid  3 , Dareen M Kanaan  4 , Subrina Farah  5 , Peter Manzo  4 , Nathan T Connell  1   6
Affiliations

Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac disease

Lauren E Merz et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: N.T.C. reports advisory board fees from Takeda, Genentech, and Medzown; consultancy fees from Takeda; travel support and honorarium from Octapharma; and holds equity in Doximity and Medzown. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Time to first International Society for Thrombosis and Haemostasis major bleed event. (A) Time to first bleed event among those with a diagnosis of AF who were prescribed any anticoagulant. (B) Time to first bleed event among those with a diagnosis of ACS who were prescribed an antiplatelet agent. Censoring occurred for death or cessation of treatment.
See this image and copyright information in PMC

References

    1. Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301–325. - PMC - PubMed
    1. Leiva O, Connors JM, Connell NT, Berger JS. Acute myocardial infarction in von Willebrand disease: characteristics and outcomes. Res Pract Thromb Haemost. 2023;7(7) - PMC - PubMed
    1. Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood. 2016;128(2):178–184. - PMC - PubMed
    1. Sanders YV, Eikenboom J, de Wee EM, et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost. 2013;11(5):845–854. - PubMed
    1. Lee CJ, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. Eur Heart J Cardiovasc Pharmacother. 2021;7(Fi1):f3–f10. - PubMed